Additional patent granted in Japan for Antaros Medical’s glucagon PET-tracer

Incretin agonists are being developed as treatment for various metabolic disorders targeting glucagon, glucagon like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors or their combination as either bi- or tri-modal incretin agonists. The development of these multimodal drugs is dependent on the understanding of the overlapping pharmacology of activating different incretin receptors.

Antaros Medical has a powerful tool set for tailoring solutions to measure receptor occupancy of both bi- and trimodal incretin agonists. Our proprietary PET tracers, [68Ga]-Tuna-2 targeting the glucagon receptor and [68Ga]S02-GIP-T4 targeting the GIP receptor, together with an additional PET-tracer for the GLP-1 receptor, can provide insights to help set dosing and generate evidence on target engagement.

Our proprietary glucagon PET-tracer has now been granted patent also in Japan, further strengthening our platform to move new metabolic treatments forward.

Read more about our incretin tracers in previous news posts:

Share on Linkedin Share on Twitter